Cost-effectiveness of interferon gamma in the treatment of community-acquired pneumonia in a hospital

Plavinsky S. L.
Doctor of Medicine, Head, Chair for Pedagogy, Philosophy and Law¹

Shabalkin P. I.
MD, PhD, Hematologist²

1 - North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia
2 - Clinic of Dr. Fomin, Moscow, Russia

Plavinsky Svyatoslav Leonidovich; e-mail: s.plavinskij@szgmu.ru

The study was sponsored by SPP «Pharmaclon» Ltd.

None declared.

Introduction. The indicators of economic damage caused by infectious diseases in 2018 increased by 1.6% compared to the previous year. Community-acquired pneumonia accounts for a significant percentage of the total number of infectious diseases and is often associated with a complicated course of influenza and acute respiratory viral infections. Purpose of the research. The present study was conducted with the aim of clinical and economic assessment of the feasibility of using gamma-interferon as part of complex treatment of community-acquired pneumonia. Materials and methods of the research. The study was based on the results of the open randomized study evaluating the effect of the drug Ingaron® (lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100,000 IU, manufactured by SPP «Pharmaclon» Ltd., Russia) on the effectiveness of antibiotic therapy and antibiotic resistance in patients with community-acquired pneumonia, which included 114 patients hospitalized for clinical reasons. Patients in the study group received gamma-interferon with antibacterial therapy; patients in the control group received only standard antibacterial therapy. The analysis of cost-utility and analysis of the impact on the budget were conducted. Results of the research and discussion. An improvement in the quality of life was revealed due to the earlier return to full health and the earlier cessation of intoxication. The strategy of prescribing gamma-interferon led to a reduction in health system costs by an average of 5629 rubles and an increase in quality of life by 0.3 days or 0.0008 QALY. The total economic gain from the appointment of gamma-interferon at 6231 rubles per patient consists of the direct gain described above and the monetary estimate of the gain in quality of life made on the basis of the willingness to pay threshold. When prescribing gamma-interferon for the treatment of community-acquired pneumonia in adults, the maximum budget savings can amount to 602 million rubles. Conclusions. Clinical and economic evaluation of the feasibility of using gamma-interferon as part of the complex treatment of community-acquired pneumonia at the hospital stage of medical care has revealed a positive impact on the quality of life and cost reduction of budgetary funds.

interferon gamma, community-acquired pneumonia, QALY, pharmacoeconomics

10.29234/2308-9113-2020-8-1-93-101

1. Chu S, Park SJ, Koo SM, et al. Incidence and Risk Factors of Pneumonia in Hospitalized Patients with Seasonal Influenza A or B. Tuberc Respir Dis (Seoul) 2017; 80(4): 392-400.

2. Muenning P. Designing and conducting cost-effectiveness analysis in medicine and health care. NY: Jossey-Bass, 2002. 356 p.

3. General'noe tarifnoe soglashenie na 2019 god: Komitet po zdravoohraneniju Sankt-Peterburga, Gosudarstvennoe uchrezhdenie «Territorial'nyj fond objazatel'nogo medicinskogo strahovanija Sankt-Peterburga», strahovye medicinskie organizacii, osushhestvljajushhie dejatel'nost' v sfere objazatel'nogo medicinskogo strahovanija v Sankt-Peterburge, Regional'naja obshhestvennaja organizacija «Vrachi Sankt-Peterburga», Territorial'naja Sankt-Peterburga i Leningradskoj oblasti organizacija profsojuza rabotnikov zdravoohranenija Rossijskoj Federacii [General Tariff Agreement for 2019: Health Committee of St. Petersburg, State Institution «Territorial Mandatory Health Insurance Fund of St. Petersburg», medical insurance companies operating in the field of compulsory health insurance in St. Petersburg, Regional public organization «Doctors of St. Petersburg », Territorial organization of St. Petersburg and the Leningrad Region of the trade union of health workers of the Russian Federation]: 28/12/2018.

4. Belevskij A. S. et al. Effektivnost' i bezopasnost' gamma-interferona pri lechenii vnebol'nichnoj pnevmonii: rezul'taty otkrytogo randomizirovannogo issledovaniya IN/100000-317 [Efficiency and safety of gamma-interferon in the treatment of community-acquired pneumonia: results of an open randomized trial IN/100000-317]. Medicina 2019; (4): 138-149.

5. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2018 godu: Gosudarstvennyj doklad. M.: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2018: State Report]. Federal'naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka [Federal Service for Supervision of Consumer Rights Protection and Human Well-Being], Moscow; 2019.

6. Shestakova I.V. et al. Federal'nye klinicheskie rekomendacii «Gripp u vzroslyh» [Federal Clinical Guidelines «Flu in Adults»]. Mezhdunarodnaja Associacija specialistov v oblasti infekcij [International Association of Specialists in the Field of Infections], Moscow, 2017.